Open AccessJournal Article
The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993
Lynne S. Peterson,Audrey M. Nelson,W. P.D. Su,Thomas G. Mason,William M. O'Fallon,Sherine E. Gabriel +5 more
363
TL;DR: Morphea, and its subtypes, are more common than previously recognized, and can lead to important disability and the survival rate was not significantly different from the general population.
read more
Abstract: Objective. To determine the incidence, prevalence, survival rates, clinical manifestations, and longterm outcome of patients with morphea (localized scleroderma) and its subtypes over a 33 year period in Olmsted County, Minnesota. Methods. We used the unique data resources of the Rochester Epidemiology Project to review all Olmsted County medical records with any potential diagnosis consistent with morphea (including plaque, generalized, bullous, linear, and deep entities) from 1960 through 1993. Results. We screened 1030 medical records and identified 82 (59 female ; 23 male) cases of morphea first diagnosed between 1960 and 1993. All cases were followed until death or migration from Olmsted County, a total of 754 person-years of observation. The annual age and sex adjusted incidence rate per 100,000 population was 2.7 (95% confidence interval 2.1, 3.3). The incidence rate increased significantly over the 33 years (p = 0.0037) on an average of 3.6% per year. The prevalence (estimated using cumulative incidence) at 80 years of age was about 2/1000. 50% of the patients had a cutaneous softening or evidence of disease resolution by 3.8 years' duration. The shortest active disease duration was found in the plaque group (50% resolution or skin softening by 2.7 years) compared to 5.5 years in the deep group. Arthralgias, synovitis, uveitis, and joint contractures were more frequent in the linear and deep categories. Although 9 patients (11%) developed some disease related disability over the followup period, this was common (44%) in the deep group. No case of morphea developed severe internal organ involvement and none progressed to systemic sclerosis. The survival rate was not significantly different from the general population (p = 0.409). Conclusion. Morphea, and its subtypes, are more common than previously recognized, and can lead to important disability.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Updated assessment of the prevalence, spectrum and case definition of autoimmune disease.
TL;DR: A comprehensive up-to-date list of the autoimmune diseases, and a tentative proposal for criteria for assigning autoimmune pathogenesis to a particular disease, are led to.
440
Update on morphea: Part I. Epidemiology, clinical presentation, and pathogenesis
Nicole Fett,Victoria P. Werth +1 more
TL;DR: Morphea, also known as localized scleroderma, is a rare fibrosing disorder of the skin and underlying tissues as mentioned in this paper and is differentiated from systemic sclerosis based on the absence of sclerodactyly, Raynaud phenomenon, and nailfold capillary changes.
352
En coup de sabre morphea and Parry-Romberg syndrome: A retrospective review of 54 patients
TL;DR: En coup de sabre morphea and Parry-Romberg syndrome frequently coexist and are likely both variants of morphea, and the efficacy of antimalarial agents and methotrexate in the treatment of these diseases remains unclear.
304
Pediatric morphea (localized scleroderma): review of 136 patients.
TL;DR: An increased prevalence of morphea in Caucasian girls, and support methotrexate as treatment for problematic forms is suggested, are suggested in a large pediatric cohort from one center, 1989 to 2006.
263
European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes.
Robert Knobler,Pia Moinzadeh,Nicolas Hunzelmann,Alexander Kreuter,Antonio Cozzio,Luc Mouthon,Maurizio Cutolo,Franco Rongioletti,Christopher P. Denton,Lidia Rudnicka,L.A. Frasin,Vanessa Smith,Armando Gabrielli,Elisabeth Aberer,Martine Bagot,G. Bali,Jean-David Bouaziz,A. Braae Olesen,I. Foeldvari,Camille Francès,A. Jalili,Ulrike Just,Veli-Matti Kähäri,Sarolta Kárpáti,K. Kofoed,Dorota Krasowska,Malgorzata Olszewska,C. Orteu,Jaana Panelius,Andrea Parodi,Antoine Petit,Pietro Quaglino,Annamari Ranki,J.M. Sanchez Schmidt,Julien Seneschal,Anna Skrok,Michael Sticherling,Cord Sunderkötter,Alain Taieb,Adrian Tanew,Philipp Wolf,Margitta Worm,Nora Wutte,T. Krieg +43 more
TL;DR: Clinicians are provided with an overview of the diagnosis and treatment of localized scleroderma, systemic sclerosis including overlap syndromes of systemic sclerosis with diseases of the rheumatological spectrum.
237
Related Papers (5)
Francesco Zulian,Balu H. Athreya,Ronald M. Laxer,A. M. Nelson,S. K. Feitosa de Oliveira,Marilynn Punaro,Ruben Cuttica,Gloria C. Higgins,L.W.A. van Suijlekom-Smit,Terry L. Moore,Carol B. Lindsley,Julia Garcia-Consuegra,M. O. Esteves Hilário,Loredana Lepore,Clovis A. Silva,Célia Machado,Stella Garay,Yosef Uziel,Giorgia Martini,Ivan Foeldvari,A. Peserico,P Woo,John I. Harper +22 more
Lynne S. Peterson,Audrey M. Nelson,W.P. Daniel Su +2 more
- 01 Nov 1995
Francesco Zulian,Cristina Vallongo,Patricia Woo,Ricardo Russo,Nicolino Ruperto,John I. Harper,Graciela Espada,Fabrizia Corona,Mukamel M,Richard Vesely,Elzbieta Musiej-Nowakowska,Jeff Chaitow,Joan Ros,Maria Teresa Apaz,Valeria Gerloni,Henryka Mazur-Zielinska,Susan Nielsen,Susanne Ullman,Gerd Horneff,Carine Wouters,Giorgia Martini,Rolando Cimaz,Ronald M. Laxer,Balu H. Athreya +23 more